OTCMKTS:AFFY Affymax (AFFY) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 10/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Affymax Stock (OTCMKTS:AFFY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Affymax alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.00▼$0.0452-Week Range$0.00▼$0.04VolumeN/AAverage Volume1,792 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Affymax, Inc. was a biotechnology company focused on developing novel therapies for serious medical conditions. The company used drug-discovery and molecular engineering technologies to identify and advance pharmaceutical candidates, with an emphasis on treatments for hematology and related disorders. Affymax’s principal product was peginesatide, an anemia treatment marketed in the United States under the brand name Omontys. The U.S. Food and Drug Administration approved Omontys in 2012 for the treatment of anemia associated with chronic kidney disease. Affymax commercialized the product through a collaboration with Takeda Pharmaceuticals. In 2013, Omontys was voluntarily recalled after reports of serious hypersensitivity reactions, including deaths. Affymax subsequently discontinued commercial operations and filed for bankruptcy protection. The company’s historical business was focused primarily on the development and commercialization of its pharmaceutical pipeline rather than on a diversified portfolio of products or broad international operations.AI Generated. May Contain Errors. Read More Receive AFFY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affymax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AFFY Stock News HeadlinesAffymax (OTCMKTS:AFFY) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?October 9, 2026 | americanbankingnews.comAffymax, Inc. (AFFY)September 14, 2024 | finance.yahoo.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Edgewise Therapeutics Appoints Arlene Morris to its Board of DirectorsMay 7, 2024 | finance.yahoo.comJasper Therapeutics Appoints Herb Cross as Chief Financial OfficerSeptember 25, 2023 | finance.yahoo.comAnaptysBio Announces Appointment of John Orwin as Chairman of the Board of DirectorsSeptember 18, 2023 | markets.businessinsider.com4 Biotech Stocks Under $5 to WatchJune 7, 2023 | thestreet.com10 Biotech Stocks on Clinical Trials WatchMay 15, 2023 | thestreet.comSee More Headlines AFFY Stock Analysis - Frequently Asked Questions How have AFFY shares performed this year? Affymax's stock was trading at $0.0008 at the start of the year. Since then, AFFY stock has increased by 5,100.0% and is now trading at $0.0416. How do I buy shares of Affymax? Shares of AFFY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:AFFY CIK1158223 Webwww.affymax.com Phone(650) 812-8700Fax650-424-0832Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta7.00 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:AFFY) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...Crypto 101 Media | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affymax Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Affymax With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
